comparemela.com

Latest Breaking News On - Fiscal year ended march - Page 1 : comparemela.com

Sakai Heavy Industries : Consolidated Financial Results for the Fiscal Year Ended March 31,2024

Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 SAKAI HEAVY INDUSTRIES, LTD. Stock code: 6358 .

United statesConsolidated business performanceFiscal year ended marchNorth americaInfrastructure investment

JCU : Financial Results Briefing Material for the Fiscal Year Ending March 2024 (Webcast)

JCU Corporation Financial Results Briefing for the Fiscal Year Ended March 2024 May 17, 2024 Event Summary .

South koreaUnited statesSouth koreanMasashi kimuraYoji inoueCorporate strategy officeResults briefingFiscal year ended marchRepresentative directorGeneral managerCorporate strategy

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomNew yorkStephanie leeSumitomo pharmaGoldman sachsMatt glineExchange commissionDevelopment expensesSecurities exchangeRoivant sciences ltdRoivant sciencesUs district courtTreatment failureGrave disease

Japan Pure Chemical : ┗ Notice Concerning the Opinion of the Board of Directors on the Shareholder Proposal （137KB） NEW

May 21, 2024 To whom it may concern JAPAN PURE CHEMICAL CO.,LTD Notice Concerning the Opinion of the Board of.

Japan generalCompany boardBoard of directors the companyShareholder proposalEnglish translationAnnual general meetingCompanies actEquity ratioGeneral meetingFiscal year ended marchMedium term management planPartial amendmentDecision making bodySurplus distributionTreasury stockShares buy back

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year .

Chau chengExchange commissionNeurology clinical development updatesDue to roivant sciences ltdGeneral clinical development updatesEndocrinology clinical development updatesImmunovant incClinical development updatesThyroid eye diseaseInsulin growth factorFiscal fourth quarter ended marchFiscal year ended marchPrivate securities litigation reform actAnnual reportRoivant sciences

vimarsana © 2020. All Rights Reserved.